KDM5D Loss

CI-VAR-00002511Explore in graph →CIViC 5326

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Prostate Neoplasm1
KDM5D Loss	Berzosertib	Predictive	D	Supports Sensitivity Response	3	submitted	EID12684 In prostate cancer cell lines with loss of the Y-linked histone demethylase KDM5D (knockdown in LNCaP and VCaP, or deletion in LNCaP-104R2 and E006AA), ATR signaling was activated, and the selective A… (full text at CIViC) PMID 29863497 · Komura et al., 2018 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.